The Chemours Company CC
Analyst Consensus
Price Objectif
Analyst historical
| Analyste | Entreprise | Prix lors de l'analyse | Prix cible | Gain potentiel | Date de publication |
|---|---|---|---|---|---|
| Joshua Spector | UBS | 15.94 $ | 21 $ | 5.06 % | 06/10/2025 |
| John Roberts | Mizuho Securities | 17.02 $ | 19 $ | 1.98 % | 23/09/2025 |
| Joshua Spector | UBS | 12.1 $ | 17 $ | 4.90 % | 07/05/2025 |
| John Roberts | Mizuho Securities | 11.28 $ | 15 $ | 3.72 % | 15/04/2025 |
| Arun Viswanathan | RBC Capital | 19.78 $ | 28 $ | 8.22 % | 11/10/2024 |
| John McNulty | BMO Capital | 19.57 $ | 32 $ | 12.43 % | 07/10/2024 |
| John McNulty | BMO Capital | 18.77 $ | 30 $ | 11.23 % | 06/08/2024 |
| John Roberts | Mizuho Securities | 23.9 $ | 25 $ | 1.10 % | 07/06/2024 |
| Rich Hilliker | UBS | 26.65 $ | 31 $ | 4.35 % | 29/05/2024 |
| John McNulty | BMO Capital | 27.05 $ | 34 $ | 6.95 % | 09/04/2024 |
| Joshua Spector | UBS | 28.74 $ | 28 $ | -0.74 % | 01/04/2024 |
| Emily Nassedd Mitsch | CFRA | 28.74 $ | 18 $ | -10.74 % | 01/04/2024 |
| Linda Bolton Weiser | D.A. Davidson | 26.84 $ | 24 $ | -2.84 % | 13/03/2024 |
| Arun Viswanathan | RBC Capital | 29.53 $ | 40 $ | 10.47 % | 01/12/2023 |
| Vincent Andrews | Morgan Stanley | 23.58 $ | 33 $ | 9.42 % | 30/10/2023 |
| Arun Viswanathan | RBC Capital | 32.55 $ | 33 $ | 0.45 % | 10/01/2023 |
| Matthew DeYoe | Bank of America Securities | 32.59 $ | 42 $ | 9.41 % | 20/05/2021 |
| Vincent Andrews | Morgan Stanley | 33.08 $ | 35 $ | 1.92 % | 10/05/2021 |
| David Coleman | Argus Research | 33.58 $ | 40 $ | 6.42 % | 06/05/2021 |